| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
101.95(B) |
| Last
Volume: |
351,356 |
Avg
Vol: |
769,142 |
| 52
Week Range: |
$692.45 - $993.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
24,729 |
84,192 |
120,701 |
282,978 |
| Total Sell Value |
$23,631,267 |
$76,701,012 |
$107,160,703 |
$220,505,683 |
| Total People Sold |
7 |
13 |
15 |
17 |
| Total Sell Transactions |
14 |
38 |
55 |
116 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schleifer Leonard S |
President & CEO |
• • – |
2021-11-19 |
4 |
D |
$651.96 |
$234,142,959 |
D/D |
(359,137) |
465,922 |
|
- |
|
| Schleifer Leonard S |
President & CEO |
• • – |
2021-11-19 |
4 |
OE |
$179.13 |
$115,030,120 |
D/D |
520,313 |
651,568 |
|
- |
|
| Sing George L |
Director |
– • – |
2021-11-18 |
4 |
S |
$650.00 |
$2,600,000 |
D/D |
(4,000) |
32,858 |
|
-7% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2021-11-17 |
4 |
AS |
$645.08 |
$439,299 |
D/D |
(681) |
25,986 |
|
9% |
|
| Sing George L |
Director |
– • – |
2021-11-16 |
4 |
S |
$650.00 |
$487,500 |
I/I |
(750) |
1,000 |
|
-8% |
|
| Sing George L |
Director |
– • – |
2021-11-16 |
4 |
S |
$650.00 |
$3,937,580 |
D/D |
(6,000) |
36,858 |
|
-8% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2021-11-16 |
4 |
D |
$651.97 |
$2,000,896 |
D/D |
(3,069) |
26,667 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2021-11-16 |
4 |
OE |
$399.66 |
$1,498,725 |
D/D |
3,750 |
29,736 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2021-11-16 |
4 |
AS |
$642.76 |
$4,638,263 |
D/D |
(7,167) |
55,705 |
|
8% |
|
| Van Plew Daniel P |
EVP & General Mgr, Industrial |
• – – |
2021-11-16 |
4 |
S |
$652.20 |
$4,452,194 |
D/D |
(6,778) |
26,931 |
|
-8% |
|
| Murphy Andrew J |
EVP Research |
• – – |
2021-11-15 |
4 |
D |
$641.50 |
$6,037,798 |
D/D |
(9,412) |
62,872 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2021-11-15 |
4 |
OE |
$52.03 |
$862,605 |
D/D |
16,579 |
72,284 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr, Industrial |
• – – |
2021-11-15 |
4 |
D |
$641.50 |
$11,689,413 |
D/D |
(18,222) |
33,709 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr, Industrial |
• – – |
2021-11-15 |
4 |
OE |
$270.43 |
$6,760,750 |
D/D |
25,000 |
51,931 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2021-11-01 |
4 |
AS |
$640.00 |
$640,000 |
D/D |
(1,000) |
17,038 |
|
4% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2021-11-01 |
4 |
OE |
$342.93 |
$342,930 |
D/D |
1,000 |
18,038 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2021-11-01 |
4 |
AS |
$638.62 |
$64,252 |
D/D |
(100) |
23,091 |
|
4% |
|
| Vagelos P Roy |
Director |
– • – |
2021-10-04 |
4 |
GD |
$0.00 |
$0 |
I/I |
347 |
141,630 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2021-10-01 |
4 |
AS |
$576.75 |
$576,750 |
D/D |
(1,000) |
17,038 |
|
12% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2021-10-01 |
4 |
OE |
$342.93 |
$342,930 |
D/D |
1,000 |
18,038 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2021-10-01 |
4 |
AS |
$560.51 |
$56,949 |
D/D |
(100) |
23,191 |
|
12% |
|
| Coles N Anthony |
Director |
– • – |
2021-09-15 |
4 |
AS |
$651.36 |
$7,873,484 |
D/D |
(11,948) |
902 |
|
-7% |
|
| Coles N Anthony |
Director |
– • – |
2021-09-15 |
4 |
OE |
$345.47 |
$4,372,807 |
D/D |
11,948 |
12,850 |
|
- |
|
| Zoghbi Huda Y |
Director |
– • – |
2021-09-14 |
4 |
AS |
$650.00 |
$648,700 |
D/D |
(998) |
891 |
|
-7% |
|
| Zoghbi Huda Y |
Director |
– • – |
2021-09-14 |
4 |
OE |
$391.92 |
$391,136 |
D/D |
998 |
1,889 |
|
- |
|
1366 Records found
|
|
Page 19 of 55 |
|
|
5.80 (0.6%) 
